| SC 13G | 2024-03-15 | GENERAL ATLANTIC, L.P. | Akero Therapeutics, Inc. | 5,233,989 | 7.7% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | Akero Therapeutics, Inc. | 2,525,252 | 4.5% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Akero Therapeutics, Inc. | 2,368,378 | 4.3% | EDGAR |
| SC 13G/A | 2024-02-14 | Redmile Group, LLC | Akero Therapeutics, Inc. | 1,109,476 | 2.0% | EDGAR |
| SC 13G | 2024-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Akero Therapeutics, Inc. | 3,681,209 | 6.6% | EDGAR |
| SC 13G | 2024-02-14 | RTW INVESTMENTS, LP | Akero Therapeutics, Inc. | 3,592,759 | 6.4% | EDGAR |
| SC 13G/A | 2024-02-13 | Avidity Partners Management LP | Akero Therapeutics, Inc. | 235,000 | 0.4% | EDGAR |
| SC 13G/A | 2024-02-13 | ALKEON CAPITAL MANAGEMENT LLC | Akero Therapeutics, Inc. | 3,764,220 | 6.8% | EDGAR |
| SC 13G/A | 2024-02-13 | JANUS HENDERSON GROUP PLC | Akero Therapeutics, Inc. | 4,306,401 | 7.7% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | Akero Therapeutics, Inc. | 3,085,048 | 5.5% | EDGAR |
| SC 13G | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Akero Therapeutics, Inc. | 2,881,989 | 5.2% | EDGAR |
| SC 13G/A | 2024-02-07 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Akero Therapeutics, Inc. | 275,000 | 0.5% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | Akero Therapeutics, Inc. | 4,180,507 | 7.5% | EDGAR |
| SC 13G/A | 2024-01-25 | STATE STREET CORP | Akero Therapeutics, Inc. | - | 9.2% | EDGAR |
| SC 13G/A | 2023-09-12 | Skorpios Trust | Akero Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G | 2023-04-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Akero Therapeutics, Inc. | 2,802,627 | 6.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | Akero Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Avidity Partners Management LP | Akero Therapeutics, Inc. | 3,825,000 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-14 | Atlas Venture Fund XI, L.P. | Akero Therapeutics, Inc. | 467,529 | 1.0% | EDGAR |
| SC 13G | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Akero Therapeutics, Inc. | 2,401,037 | 5.1% | EDGAR |